

Friday 27th October 2023		
Olivia Newton-John Cancer Research Institute		
8:00 - 9:00	Registration	
9:00 - 10:55 09:00 - 09:05	Session 1: CRISPR biology and emerging technologies  Conference opening & Acknowledgement of Country	V
09:05 - 09:35	Accelerated drug-resistant variant discovery with an enhanced, scalable	Ben Haley (Centre de recherche de l'Hôpital
09.03 - 09.53	mutagenic base editor platform	Maisonneuve-Rosemont, Canada)
09:35 - 10:00	Harnessing CRISPR and microbial dark matter for biotechnology	Gavin Knott (Monash BDI)
10:00 - 10:15	Elucidating CRISPR-Cas13 target search mechanisms in live human cells	Gurjeet Gill Kaur Jagjeet Singh (Peter Mac)
10:15 - 10:40	Developing CRISPR gene drives for feral rodent population suppression	Paul Thomas (SAHMRI)
10:40 - 10:55	Flash talks #1	Honglin Chen, Soo Jen Low,
10:55 - 11:15	Break	Fatimah Jalud, Wei Jin
11:15 - 12:30	11:15 - 12:30 Session 2: High-throughput screening and functional genomics	
11:15 - 11:40	Whole genome CRISPR-Cas9 screening to improve therapy for aggressive blood	Sarah Diepstraten (WEHI)
	cancers	
11:40 - 11:55	CRISPR activation of non-coding autoimmune risk loci in primary human B cells	Viacheslav Kriachkov (WEHI)
11:55 - 12:10	Combining CRISPR screening, scRNAseq and spatial techniques to study	Gaoyuan Wang (ONJCRI/WEHI)
	venetoclax resistance mechanisms in aggressive lymphomas	Marina Leiwe, Kok Fei Chan,
12:10 - 12:30	Flash talks #2	Amber Aslop, Yexuan Deng,
12:30 - 13:00	Lunch	Ebithal Mustafa, Amali Cooray
13:00 - 13:45	Poster viewing	
13:45 - 15:10	Session 3: Novel gene editing and delivery strategies	
13:45 - 14:15	Peptide-enabled CRISPR enzyme delivery for versatile <i>ex vivo</i> T cell engineering and <i>in vivo</i> editing of the brain	Dana Foss (Related Sciences, USA)
14:15 - 14:40	TBA	Pilar Blancafort (Harry Perkins Institute
		of Medical Research, WA)
14:40 - 14:55	Potent, HIV-specific latency reversal through CRISPR activation delivered by	Paula Cevaal (Peter Doherty Institute)
	lipid nanoparticles	
14:55 - 15:10	CRISPR-HDR engineering of T cells for immunotherapy purposes	Maria Nogueira de Menezes (Peter Mac)
Break		
15:30 - 17:00	Session 4: Disease biology and therapeutic application	
15:30 - 15:55	RNA targeting with CRISPR-Cas13: from fundamental principles to therapeutic applications	Mohamed Fareh (Peter Mac)
15:55 - 16:10	Exploiting CRISPR-Cas technology for novel diagnostics - responding to the monkeypox virus outbreak	Shivani Pasricha (WEHI)
16:10 - 16:25	CRISPR-Cas9 engineering of next-generation armoured CAR T-cells	Amanda Chen (Peter Mac)
16:25 - 16:50	Finding new tumour drivers by using advanced CRISPR screening techniques in vivo	Marco Herold (ONJCRI)
16:50 - 17:00	Closing remarks & prizes	
17:00 - 18:30	Networking session	

## Generously supported by:















